Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash & Current Investments (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Cash & Current Investments readings, the most recent being $293.5 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 17.44% to $293.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $293.5 million, a 17.44% increase, with the full-year FY2025 number at $293.5 million, up 17.44% from a year prior.
  • Cash & Current Investments hit $293.5 million in Q4 2025 for Amicus Therapeutics, up from $263.8 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $557.0 million in Q3 2021 to a low of $231.0 million in Q2 2025.
  • Median Cash & Current Investments over the past 5 years was $283.2 million (2023), compared with a mean of $321.2 million.
  • Biggest five-year swings in Cash & Current Investments: rose 23.73% in 2021 and later plummeted 39.15% in 2022.
  • Amicus Therapeutics' Cash & Current Investments stood at $482.5 million in 2021, then plummeted by 39.15% to $293.6 million in 2022, then fell by 2.52% to $286.2 million in 2023, then decreased by 12.67% to $249.9 million in 2024, then increased by 17.44% to $293.5 million in 2025.
  • The last three reported values for Cash & Current Investments were $293.5 million (Q4 2025), $263.8 million (Q3 2025), and $231.0 million (Q2 2025) per Business Quant data.